Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Moderately to Severely Active Ulcerative Colitis (Phase 2b/3)
2018-004002-25Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Guselkumab with Placebo (2 arms). Primary endpoint: Clinical response at induction Week 12. Started Jul 2019; status: active.
02
Drugs
guselkumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2018-004002-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004002-25.